Sharp Therapeutics Corp.
SHRXF
$1.00
$0.4375.72%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -554.65% | 62.39% | -626.88% | -59.73% | 89.64% |
| Total Depreciation and Amortization | -3.91% | -17.84% | -48.90% | 472.73% | 177.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 99.52% | -100.32% | 146.11% | 388.82% | -299.85% |
| Change in Net Operating Assets | -55.29% | 143.77% | 461.24% | 36.95% | -67.61% |
| Cash from Operations | 14.04% | 18.01% | 33.47% | -28.50% | -95.71% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -12.20% | -12.20% | 82.57% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -99.31% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -70.44% | 1,537.80% | -100.31% | -- | 102.68% |
| Foreign Exchange rate Adjustments | -111.50% | 87.31% | -834.43% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.60% | 70.98% | -132.16% | -4,008.11% | 2,873.49% |